Pfizer announces FDA acceptance for review of NDA for ELJANZ® (tofacitinib citrate)
Pfizer announced the FDA accepted for review Pfizer’s new drug application for XELJANZ® (tofacitinib citrate) 11 mg once daily modified release tablets for treatment of moderate to severe rheumatoid arthritis in patients who have had an inadequate response or intolerance to methotrexate. July 03, 2015